ClinicalTrials.gg
CompletedNCT03590379TRI-DUpdated Apr 12, 2021

Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 interventional study of CHF 5993 DPI and CHF5993 pMDI in Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Bulgaria. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-04-12.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
366
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Chiesi Farmaceutici S.p.A..

Enrollment
16th of 59
366 · median 65
Started
2018
with 1 other
Phase 2
15 of 68
none open now
Registered
42nd of 68
by date

Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., this one is the 16th largest by enrollment of the 59 interventional ones that give a count, is one of 2 that started in 2018, is one of 15 in phase 2, and was the 42nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

5 of the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of Fixed Combination of Beclomethasone Dipropionate + Formoterol Fumarate + Glycopyrronium Bromide Administered Via Dry Powder Inhaler in COPD

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adults (40 ≤ age ≤ 85 years) with a diagnosis of ;
  • Current smokers or ex-smokers;
  • A Post-bronchodilator ≥30% and \<80% of the predicted normal value and FEV1/FVC (Forced Vital Capacity) \< 0.7;
  • Patients' COPD therapy (stable regimen at least 30 days before screening) with either:

    • Inhaled /long-acting β2-agonist/long-acting muscarinic antagonist (free or fixed) combination
    • Inhaled corticosteroids/long-acting β2-agonist (free or fixed) combination
    • Inhaled long-acting β2-agonist/long-acting muscarinic antagonist (free or fixed) combination
    • Inhaled long-acting muscarinic antagonist alone.

Exclusion criteria

Exclusion Criteria:

  • Pregnant and lactating women;
  • Diagnosis of asthma;
  • Known respiratory disorders other than ;
  • Patients treated for a moderate or severe COPD exacerbation within 6 weeks prior to screening or during the run-in period;
  • Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia;
  • Patients who have cardiovascular condition;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
366 participants (actual)

Study arms

  • Experimental
    CHF 5993 DPI

    BDP/FF/GB DPI 100/6/12,5 mcg

    Drug: CHF 5993 DPI · Drug: Placebo pMDI

  • Active comparator
    CHF 5993 pMDI

    BDP/FF/GB pMDI 100/6/12,5 mcg

    Drug: CHF5993 pMDI · Drug: Placebo DPI

  • Active comparator
    CHF 1535 pMDI

    BDP/FF pMDI 100/6 mcg

    Drug: CHF 1535 pMDI · Drug: Placebo DPI

Interventions

  • BDP/FF/GB DPI

  • BDP/FF/GB pMDI

  • BDP/FF pMDI

  • DrugPlacebo DPI

    CHF 5993 DPI matched placebo

  • DrugPlacebo pMDI

    CHF 5993 pMDI matched Placebo (direct blinding of active CHF 5993 and CHF 1535 pMDIs)

06

What researchers measure

Primary outcomes

  1. FEV1 AUC0-12h (Area Under the Curve for Forced Expiratory Volume in 1 second measured serially for 0-12 hours) normalised by time (L) on dosing Day 28

    To demonstrate the non-inferiority between CHF 5993 DPI and CHF 5993 pMDI in terms of FEV1 AUC0-12h normalized by time, in COPD patients

    Time frame: Day 28

  2. Trough FEV1 at 24 hours (L) on dosing Day 28.

    To demonstrate the non-inferiority between CHF 5993 DPI and CHF 5993 pMDI in terms of trough FEV1 at 24h on dosing Day 28 in COPD patients

    Time frame: Day 28

Secondary outcomes

  1. Change from baseline in pre-dose morning FEV1 (L) on Day 28

    To evaluate the efficacy of CHF 5993 DPI on other lung function parameters and clinical outcome measures.

    Time frame: from Baseline to Day 28

  2. Change from baseline in FEV1 AUC0-4h normalised by time (L) on Day 28

    To evaluate the efficacy of CHF 5993 DPI on other lung function parameters and clinical outcome measures.

    Time frame: from Baseline to Day 28

  3. Change from baseline in FEV1 AUC0-12h normalised by time (L) on Day 1

    To evaluate the efficacy of CHF 5993 DPI on other lung function parameters and clinical outcome measures.

    Time frame: from Baseline to Day 1

07

Study locations

1 site
  • Medical Center Convex EOOD
    Sofia, 1680, Bulgaria
08

References and documents

Publications

  • Beeh KM, Kuna P, Corradi M, Viaud I, Guasconi A, Georges G. Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial. Int J Chron Obstruct Pulmon Dis. 2021 Jan 14;16:79-89. doi: 10.2147/COPD.S291030. eCollection 2021. PubMed 33488071 ↗

Individual participant data

Plan to share: Yes — Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared Patient-level Data is anonymized to protect personally identifiable information. Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Access criteria: Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Data sharing details ↗ · www.chiesi.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Oct 2018, 4 months.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 4 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2018
First posted
Jul 18, 2018
StartActual
Jun 15, 2018
Primary completionActual
Oct 16, 2018
CompletionActual
Mar 6, 2019
Last update
Apr 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03590379
Responsible party
Sponsor
First posted
Jul 18, 2018
Start date
Jun 15, 2018
Primary completion
Oct 16, 2018
Completion
Mar 6, 2019
Last update
Apr 12, 2021

Study contacts

Kai-Michael Beeh, MD
principal investigator · Institut fuer Atemwegsforschung GmbH, Wiesbaden, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CHF5993

Start the discussion